Targeting autophagy by HCQ makes KL lung tumors sensitive to the MEK inhibitor Trametinib, prompting us to further elucidate the potential underlying mechanism of tumor regression caused by the combination therapy. The gene discussed is MAP2K7; the disease is neoplasm.